Alebund Pharmaceuticals (Jiangsu)'s (HKG:9637) new drug application for AP301 capsules was accepted for review by China's National Medical Products Administration.
The drug has been developed for the treatment of hyperphosphatemia in patients with chronic kidney disease receiving maintenance dialysis.
Obayashi (TYO:1802) posted an 116% year-over-year increase in profit attributable to owners of the parent to 39.1 billion yen for the three months ended June 30 from 18.1 billion yen.The Japan-based construction company's basic earnings per share increased to 56.87 yen from 25.59 yen a year ago, according to a Tokyo Stock Exchange filing on Friday.Net sales jumped 19% to 623.4 billion yen from 523.8 billion yen in the year-ago period.For the fiscal year ending March 31, 2027, the company forecasts an attributable profit of 157 billion yen, a basic EPS of 228.39 yen, and net sales of 3 trillion yen.The company plans to pay a second quarter-end dividend of 47 yen per share for the current fiscal year.
HMM (KRX:011200) is still in discussion with a counterparty to secure ultra-long-term contracts for bulk carriers, according to a Friday filing with the Korea Exchange.The disclosure is in response to a July 9 media report on the matter.The company will release another disclosure within three months or when specific details are finalized.Shares of the company rose more than 1% in recent trade.
SJEE Engineering, a subsidiary of Southern Score Builders Berhad (KLSE:SSB8), has secured an order worth 146.5 million ringgit from a local construction company to undertake a subcontract project, according to a Thursday filing with Bursa Malaysia.The company's shares were up nearly 2% in Friday's trade.The subcontract project is for Electrical Package 3 Works for a data center project, and is expected to be completed by Jan. 15, 2028.The project is expected to contribute positively to the net assets and earnings per share of the company from the financial year ending June 30, 2027, until the completion of the project.